AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01671774
Drug: IMAB362
RxNorm normalized name: immunoglobulin G1, anti-(human Claudin-18.2) (human-mus musculus monoclonal IMAB362 heavy chain), disulfide with human-mus musculus monoclonal IMAB362 .kappa.-chain, dimer
DrugBank: Zolbetuximab (DB15118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/m2 on d 1 of cycle 1. 600 mg/m2 on d 1 of every other cycle
Trial: NCT01671774
Drug: Interleukin-2 (1 million IU)
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 million IU on day 1, 2 and 3 of cycles 1 and 3.
Trial: NCT01671774
Drug: Interleukin-2 (3 million IU)
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 million IU on day 1, 2 and 3 of cycles 1 and 3.
Trial: NCT03043989
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 infusions of Docetaxel with 18 doses clarithromycin
Trial: NCT03043989
Drug: Cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 infusions of Cabazitaxel with 18 doses clarithromycin
Trial: NCT01734928
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide 4 mg will be taken orally on Days 1-14 of a 21-day cycle.
Trial: NCT01734928
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib 1.3 mg/m2 will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression.
Trial: NCT01734928
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\>75 years old\] will be taken orally on Days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
Trial: NCT00620035
Drug: Radiopaque Etonogestrel Implant
RxNorm normalized name: etonogestrel Drug Implant
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One implant inserted for a 3-year treatment period
Trial: NCT04029038
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01517776
Drug: Cilengitide
RxNorm normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilengitide 1800 mg/m² i.v. twice weekly with a mandatory platelet-count dependent dose adaptation rule
Trial: NCT01517776
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide 75 mg/m²/d p.o. for 6 weeks, followed by 1 week rest with a mandatory platelet-count dependent dose adaptation rule
Trial: NCT03076164
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib 1.5mg once daily by mouth
Trial: NCT03076164
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib 75mg once daily by mouth
Trial: NCT02209909
Drug: aspirin continuation
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are randomized to continue aspirin before OPCAB surgery.
Trial: NCT02209909
Drug: aspirin discontinuation
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are randomized to discontinue aspirin more than 4 days before OPCAB surgery.
Trial: NCT01014156
Drug: epoprostenol
RxNorm normalized name: Epoprostenol
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: titration up to 4 ng/kg/min
Trial: NCT04986813
Drug: Tranexamic acid injection
RxNorm normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g of TXA in 100 ml of normal saline
Trial: NCT04457778
Drug: M6223
RxNorm normalized name: Metformin hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive an intravenous (IV) infusion of M6223 at escalated doses every 2 weeks (Q2W) or every 3 weeks (Q3W) on Day 1 of each Cycle (Each cycle is of 14 days) according to the recommendation of the SMC(Safety Monitoring Committee) until the maximum tolerated dose(MTD) has been reached or confirmed disease progression.
Trial: NCT04457778
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive an IV infusion of bintrafusp alfa Q2W on Day 1 of each Cycle (Cycle is 14 days) until confirmed disease progression.
Trial: NCT04457778
Drug: M6223
RxNorm normalized name: Metformin hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive an IV infusion of M6223 at escalated doses Q2W on Day 1 of each Cycle (Each cycle is of 21 days) according to the recommendation of the SMC until the MTD has been reached or confirmed disease progression.
Trial: NCT03153293
Drug: rAAV2-ND4
RxNorm normalized name: rAAV2-ND1
DrugBank: NFS-02 (DB18422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a Single IVT Injection
Trial: NCT02697929
Drug: sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02697929
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01654250
Drug: NWP09
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Methylphenidate, variable dose, daily dosing, 1 week duration
Trial: NCT04430621
Drug: Follicle Stimulating Hormone
RxNorm normalized name: follicle stimulating hormone
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FSH will be administered s.c. in the morning to male healthy subjects
Trial: NCT02618733
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90mg, twice a day
Trial: NCT02618733
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 75mg, once a day
Trial: NCT00680836
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 550 mg orally two times per day for 14 days
Trial: NCT00265005
Drug: alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iv administration of 1 mg/ml up to two times and 2 mg/ml if needed.
Trial: NCT01531803
Drug: Normal Saline Solution
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal (0.9%) saline solution administered via IV infusions of 10 to 20 mL/kg as appropriate per standard of care based on the subject's clinical status and response to treatment.
Trial: NCT03881878
Drug: TAHP and AHP
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Tastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with pCR:D1 X 11-12 cycles, q3weeks~* Atezolizumab (1200mg, IV)~* Trastuzumab (600mg, SC)~* Pertuzumab (420mg, IV)
Trial: NCT00675233
Drug: HPPH
RxNorm normalized name: HPPH
DrugBank: 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (DB15243)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01034657
Drug: Epoetin Alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa was supplied as 10000 IU/1 mL in a ready-to-use syringe.
Trial: NCT02044146
Drug: Ticagrelor, Prasugrel, Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02217007
Drug: SNC-102 sustained release tablet
RxNorm normalized name: Immunoglobulin g1-lambda, anti-(homo sapiens snca (synuclein alpha, alpha-synuclein, park1, park4, parkinson disease (autosomal dominant, lewy body) 4, non a4 component of amyloid precursor, nacp)), monoclonal antibodygamma1 heavy chain (1-442) (vh (homo
DrugBank: Cinpanemab (DB16127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNC-102 is an 800 mg tablet. It will be administered twice daily (morning and evening) for a total of 8 weeks: the initial 4 weeks will be 1 tablet in the morning and 1 tablet in the evening; the next 4 weeks will be 2 tablets in the morning and 1 tablet in the evening.
Trial: NCT00330278
Drug: Cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03675555
Drug: Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each patient received 30 mg Mirta tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline \[NS\]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
Trial: NCT03675555
Drug: Dexamethasone phosphate
RxNorm normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
Trial: NCT01494857
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab 40 mg from 4 to 1 injection once in two weeks. Total Treatment period - 10 weeks.
Trial: NCT04431778
Drug: Ethosuximide
RxNorm normalized name: Ethosuximide
DrugBank: Ethosuximide (DB00593)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks).
Trial: NCT00159874
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, subjects with body weight ≥8 - 20 kg: 20 mg 3 times a day (tid) subjects with body weight \>20 - 45 kg: 40 mg 3 times a day (tid) subjects with body weight \>45 kg: 80 mg 3 times a day (tid)
Trial: NCT00159874
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral,10 mg 3 times a day (tid), only subjects with body weight \>20 kg
Trial: NCT00159874
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, subjects with body weight ≥8 - 20 kg: 10 mg 3 times a day (tid); subjects with body weight \>20 - 45 kg: 20 mg 3 times a day (tid); subjects with body weight \>45 kg: 40 mg 3 times a day (tid)
Trial: NCT01266057
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose of 200 mg by mouth every day for a 21 day cycle.
Trial: NCT01266057
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose of 2 mg by mouth every day for a 21 day cycle.
Trial: NCT01266057
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose of 200 mg by mouth per day for a 21 day cycle.
Trial: NCT03302936
Drug: Phenazopyridine
RxNorm normalized name: Phenazopyridine
DrugBank: Phenazopyridine (DB01438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: to be given preoperatively
Trial: NCT01436890
Drug: Revamilast
RxNorm normalized name: Revamilast
DrugBank: Revamilast (DB11838)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet. Low dose, Once daily for 12 weeks
Trial: NCT01436890
Drug: Revamilast
RxNorm normalized name: Revamilast
DrugBank: Revamilast (DB11838)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose, Once daily for 12 weeks
Trial: NCT01436890
Drug: Revamilast
RxNorm normalized name: Revamilast
DrugBank: Revamilast (DB11838)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose, Once daily for 12 weeks
Trial: NCT04297267
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1250mg/m2,d1,d8,every 3 weeks
Trial: NCT04297267
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75mg/m2,d1，every 3 weeks
Trial: NCT03760640
Drug: Insulin Lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered SC
Trial: NCT01008046
Drug: combined metformin-CC
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
Trial: NCT01431573
Drug: Lithium
RxNorm normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For patients not already taking lithium, dose will start at 600 mg daily (all in the evening) and be adjusted in 300 mg/d increments according to weekly blood levels (i.e., lithium dose may be changed once a week if most recent blood level is too low; if too high, it will be decreased or temporarily discontinued as clinically indicated; 150 mg increments will be utilized if multiples of 300 mg result in intolerance or blood levels outside the target range (0.6 - 1.0 mEq/L)
Trial: NCT02631031
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single oral dose of 160 mg valsartan under fasting conditions
Trial: NCT00638079
Drug: Megestrol acetate oral suspension 625 mg/5 mL
RxNorm normalized name: megestrol acetate Oral Suspension
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered with a high fat meal
Trial: NCT00638079
Drug: Megestrol acetate oral suspension 625 mg/5 mL
RxNorm normalized name: megestrol acetate Oral Suspension
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered following an overnight fast
Trial: NCT00892450
Drug: Oxybutynin and darifenacin
DrugBank: Darifenacin (DB00496)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants with overactive bladder will take each medication for 4 weeks.
Trial: NCT04579419
Drug: Sodium Bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Botulinum Toxin diluted in Sodium Bicarbonate
Trial: NCT00122863
Drug: Duloxetine Hydrochloride
RxNorm normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03059888
Drug: Abatacept Injection
RxNorm normalized name: abatacept Injection
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous administration of abatacept
Trial: NCT03982693
Drug: Edetate Disodium
RxNorm normalized name: Edetate Disodium
DrugBank: Edetate disodium anhydrous (DB14600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The solution contains up to 3 g of edetate disodium adjusted based on creatinine clearance, 2 g of magnesium chloride, 100 mg of procaine hydrochloride, 2500 U of heparin, 7 g of ascorbate, 2 milliequivalent (mEq) potassium chloride (KCl), 840 mg sodium bicarbonate, 250 mg pantothenic acid, 100 mg of thiamine, 100 mg of pyridoxine, and sterile water to complete 500 mL.
Trial: NCT02344355
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy.~Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days.~For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days.~If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days.
Trial: NCT05639803
Drug: PEGIFNα1b
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100μg/vial
Trial: NCT03365908
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mL of 0.5% ropivacaine will be administered for the adductor canal block
Trial: NCT02098538
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All eligible patients will receive a starting regorafenib dose of 120 mg daily taken orally for 3 weeks in a 4-week cycle. Patients for whom regorafenib dose reduction was not performed or required may have their treatment dose increased to the FDA-approved dose of 160 mg daily orally for 3 weeks in a 4-week cycle in cycle #2 or beyond (this is not mandatory). RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity
Trial: NCT03586609
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC or IV
Trial: NCT03586609
Drug: Cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03586609
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given SC
Trial: NCT03586609
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT00720811
Drug: amoxycillin
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amoxycillin 250mg tab 4-12 months: 1/2x2; 13-35 months: 1x2; 36-59 months: 11/2x2
Trial: NCT00720811
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: paracetamol 500mg tablet \<36months: 1/4x4 for 2 days; 36-59months: 1/2x4 for 2 days
Trial: NCT02314247
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-4 of each 4-week cycle (Protocol V.3.0).~20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-3 of each 4-week cycle (Protocol V.\<3.0).~Number of Cycles: up to 12 but there is no maximal duration for treatment.
Trial: NCT01766843
Drug: Seretide Diskus
RxNorm normalized name: seractide
DrugBank: Seractide acetate (DB09334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 inhalations as a single dose
Trial: NCT01766843
Drug: SF Easyhaler
RxNorm normalized name: light green SF yellowish
DrugBank: Light green SF yellowish (DB11183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations as a single dose
Trial: NCT03997838
Drug: VVZ-149 Injections
RxNorm normalized name: Vvz-149 free base
DrugBank: Opiranserin (DB16271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of 1000 mg of VVZ-149
Trial: NCT00510471
Drug: autologous immunoglobulin idiotype-KLH conjugate vaccine
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02809781
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50mg,hypodermic injection,once per week, for 12 weeks
Trial: NCT01209130
Drug: DCDT2980S
RxNorm normalized name: DCDT2980S
DrugBank: Pinatuzumab vedotin (DB15432)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT03941262
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death-ligand 1 (PD-L1).
Trial: NCT01209130
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous repeating dose
Trial: NCT03941262
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death receptor-1 (PD-1).
Trial: NCT03374332
Drug: Gemtuzumab Ozogamicin (GO)
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be given gemtuzumab ozogamicin on days 1,4, and 7. Capped at 4.5mg individual doses. Total doses capped at 13.5mg.